Short answer
West Pharmaceutical Services (WST) filed an 8-K current report with the SEC on June 1, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Michel Lagarde becomes President and CEO August 31, 2026, replacing retiring Eric Green.
West Pharmaceutical Services 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Michel Lagarde becomes President and CEO August 31, 2026, replacing retiring Eric Green
- Leadership continuity: Green exits the Board; Lead Independent Director Robert Friel becomes Chair
- New CEO brings Thermo Fisher, Patheon, and healthcare-services experience, potentially strengthening pharma-market expertise
- 2026 compensation includes $1.175M salary, $1.469M target bonus, and $8.611M prorated LTI grant
- Additional inducement equity capped at $10M, with matching awards tied to up to $2.5M of personal stock purchases
Other items in this filing:
- Item 7.01: Regulation FD Disclosure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other West Pharmaceutical Services 8-K filings
Get the next WST 8-K as it lands
Follow WST for push alerts, or ask the research agent what this filing means.